308 related articles for article (PubMed ID: 18219261)
1. Ixabepilone (Ixempra) for breast cancer.
Med Lett Drugs Ther; 2008 Jan; 50(1278):7-8. PubMed ID: 18219261
[No Abstract] [Full Text] [Related]
2. Ixabepilone: new drug. Similar to taxanes, but no better.
Prescrire Int; 2009 Aug; 18(102):160. PubMed ID: 19743574
[No Abstract] [Full Text] [Related]
3. Successful rechallenge after ixabepilone-induced radiation recall dermatitis using an alternative dosing strategy.
Ford JN; Newton M; Jordan C; Abraham J
J Oncol Pharm Pract; 2013 Mar; 19(1):89-92. PubMed ID: 22323422
[TBL] [Abstract][Full Text] [Related]
4. Approved agents for metastatic breast cancer.
Fornier MN
Semin Oncol; 2011 Jun; 38 Suppl 2():S3-10. PubMed ID: 21600382
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
[TBL] [Abstract][Full Text] [Related]
6. Current perspectives of epothilones in breast cancer.
Cardoso F; de Azambuja E; Lago LD
Eur J Cancer; 2008 Feb; 44(3):341-52. PubMed ID: 18178426
[TBL] [Abstract][Full Text] [Related]
7. Epothilones: clinical update and future directions.
Donovan D; Vahdat LT
Oncology (Williston Park); 2008 Apr; 22(4):408-16; discussion 416, 421, 424 passim. PubMed ID: 18472615
[TBL] [Abstract][Full Text] [Related]
8. Ixabepilone, a novel epothilone analog in the treatment of breast cancer.
Pivot X; Villanueva C; Chaigneau L; Nguyen T; Demarchi M; Maurina T; Stein U; Borg C
Expert Opin Investig Drugs; 2008 Apr; 17(4):593-9. PubMed ID: 18363523
[TBL] [Abstract][Full Text] [Related]
9. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
Rivera E; Lee J; Davies A
Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
[TBL] [Abstract][Full Text] [Related]
10. Epothilones in the treatment of cancer.
Larkin JM; Kaye SB
Expert Opin Investig Drugs; 2006 Jun; 15(6):691-702. PubMed ID: 16732719
[TBL] [Abstract][Full Text] [Related]
11. Ixabepilone in metastatic breast cancer: complement or alternative to taxanes?
Tan AR; Toppmeyer DL
Clin Cancer Res; 2008 Nov; 14(21):6725-9. PubMed ID: 18980963
[No Abstract] [Full Text] [Related]
12. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
[TBL] [Abstract][Full Text] [Related]
13. Alternative dosing schedules and administration updates for ixabepilone.
Kossoff E
J Oncol Pharm Pract; 2011 Sep; 17(3):203-8. PubMed ID: 20215481
[TBL] [Abstract][Full Text] [Related]
14. Advances in breast cancer treatment: the emerging role of ixabepilone.
Frye DK
Expert Rev Anticancer Ther; 2010 Jan; 10(1):23-32. PubMed ID: 20014882
[TBL] [Abstract][Full Text] [Related]
15. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
Yardley DA
Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
Halterman PA
Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
[TBL] [Abstract][Full Text] [Related]
17. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
Boehnke Michaud L
J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
[TBL] [Abstract][Full Text] [Related]
18. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M
Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
[TBL] [Abstract][Full Text] [Related]
19. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
[TBL] [Abstract][Full Text] [Related]
20. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
Vahdat L
Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]